Pharmacokinetics, Safety, Efficacy, and Biomarker Profiles During Nemolizumab Treatment of Atopic Dermatitis in Adolescents
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Nemolizumab, a new monoclonal antibody that targets the receptor alpha of the neuroimmune cytokine interleukin-31 (IL-31), has shown efficacy in atopic dermatitis (AD) in adults. This study evaluated the pharmacokinetics (PK) and safety of nemolizumab in adolescents with moderate to severe AD as well as the relationship between nemolizumab concentrations and clinical efficacy and the effect of nemolizumab on protein biomarkers. METHODS: Open-label, 16-week study of nemolizumab in patients aged 12-17 years with moderate to severe AD (baseline EASI ≥ 16, IGA ≥ 3, and BSA ≥ 10%) and associated pruritus with baseline average daily peak pruritus numeric rating scale (PP-NRS) intensity of at least 4. Nemolizumab was administered subcutaneously as a loading dose of 60 mg at baseline, followed by 30 mg every 4 weeks until week 12 with background topical corticosteroids (TCS) or calcineurin inhibitors (TCI). Subsequently patients were followed for 8 weeks more. Stratum corneum (SC) and plasma samples were collected for biomarker assessments. RESULTS: Twenty patients participated, with a mean age of 14.8 ± 1.6 years. The PK of nemolizumab was described by a one-compartment model with linear elimination, a first-order absorption, and a mean half-life of 16.7 ± 4.1 days. Mean trough concentrations ranged from 2935 ± 1029 ng/mL to 3292 ± 2018 ng/mL over the 16-week treatment period. There was a marked improvement in rash, itch, and sleep with a decrease from baseline to week 16 in EASI by 66.5 ± 32.5%, in PP-NRS by 43.2 ± 37%, and in sleep disturbance numeric rating scale by 53.5 ± 47.8%. The popPK and PK/PD analyses confirmed that model-predicted exposure and efficacy of nemolizumab were similar in adolescents compared to adults receiving the same dosing regimens. Age did not impact PK parameters, while the main source of PK variability was body weight. Analyses of SC samples identified a panel of AD-related pro-inflammatory biomarkers that were upregulated in lesional skin (compared to non-lesional skin) and correspondingly downregulated in clinical responders to nemolizumab (based on EASI75 and PP-NRS ≥ 4). Four biomarkers (CCL20, CCL22, CCL27, and VEGF) had changes that were 1.9-3.5-fold higher in EASI responders than in EASI non-responders (all p < 0.05). Analysis showed no significant correlation between plasma biomarkers and clinical scores. Adverse events were experienced by 33.3% of subjects (n = 6) and were primarily mild or moderate in severity. CONCLUSIONS: Nemolizumab PK and safety profiles in adolescents with moderate to severe AD are consistent with previous nemolizumab studies in adults. PK/PD models demonstrate similar exposure-response profiles in 12- to 17-year-old adolescents and adults for three clinical endpoints (EASI, IGA, and PP-NRS). Nemolizumab treatment reversed AD-related pro-inflammatory biomarkers in skin, indicating that the neuroimmune cytokine IL-31 is an important mediator of multiple pathways in AD. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov NCT03921411.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Weidinger, S., & Novak, N. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00149-x · Cited by 1,908
Weidinger, S., Beck, L. A., Bieber, T., Kabashima, K., & Irvine, A. D. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0001-z · Cited by 1,549
Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis
Ruzicka, T., Hanifin, J. M., Furue, M., Pulka, G., Mlynarczyk, I., Wollenberg, A., Galus, R., Etoh, T., Mihara, R., Yoshida, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606490 · Cited by 592
Biomarkers in atopic dermatitis—a review on behalf of the International Eczema Council
Renert-Yuval, Y., Thyssen, J. P., Bissonnette, R., Bieber, T., Kabashima, K., Hijnen, D., & Guttman-Yassky, E. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.01.013 · Cited by 350 · cited 8×
“Four biomarkers (CCL20, CCL22, CCL27, and VEGF) had changes that were 1.9–3.5-fold higher in EASI responders than in EASI non-responders (all p\0.05).”
BackgroundInfluentialSilverberg, J. I., Pinter, A., Pulka, G., Poulin, Y., Bouaziz, J.-D., Wollenberg, A., Murrell, D. F., Alexis, A., Lindsey, L., Ahmad, F., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.08.013 · Cited by 271
Self-citationItch in Atopic Dermatitis – What Is New?
Legat, F. J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.644760 · Cited by 82
Cited by
CLA+ memory T cells in atopic dermatitis: CLA+ T cells and atopic dermatitis
Nicolàs, L. S. S., Czarnowicki, T., Akdis, M., Pujol, R. M., Lozano‐Ojalvo, D., Leung, D. Y. M., Guttman‐Yassky, E., & Santamaria‐Babí, L. F. (2024) · Allergy · doi:10.1111/all.15816 · Cited by 25
“114 Additionally, it was suggested that plasma levels of HDM-specific IgE may stratify moderate- to-severe AD patients and hopefully be useful for identifying patients more probable to be responders for IL- 31-directed therapies.”
BackgroundGorelick, J., Nguyen, A., Schneider, S. K. R., Martel, B. C., Madsen, D. E., & Armstrong, A. W. (2025) · American Journal of Clinical Dermatology · doi:10.1007/s40257-024-00913-9 · Cited by 18
“Studies with traloki-numab, dupilumab, lebrikizumab, and nemolizumab (targets IL-31RA), as well as the JAK1 inhibitors upadacitinib and abrocitinib, have commonly shown decreased serum levels of biomarkers such as CCL17/TARC, eosinophil cell count, and IgE [65–70].”
Ewulu, A. R., Prajapati, S., & Feldman, S. R. (2023) · Immunotherapy · doi:10.2217/imt-2022-0307 · Cited by 10
Metadata
- Authors
- Sidbury, R., Alpizar, S., Laquer, V., Dhawan, S., Abramovits, W., Loprete, L., Krishnaswamy, J. K., Ahmad, F., Jabbar-Lopez, Z., & Piketty, C.
- Venue
- Dermatology and Therapy
- Published
- 2022-01-28
- Volume
- 12
- Issue
- 3
- Pages
- 631-642
- ISSN
- 2190-9172 (ISSN-L)
- 2193-8210
- OpenAlex
- W4210759904
- Cited by
- 38
- References
- 6
- FWCI
- 6.84
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacokinetics, Safety, Efficacy, and Biomarker Profiles During Nemolizumab Treatment of Atopic Dermatitis in Adolescents. https://app.cochat.ai/papers/10.1007/s13555-021-00678-7
- The paper
- Sidbury, R., Alpizar, S., Laquer, V., Dhawan, S., Abramovits, W., Loprete, L., Krishnaswamy, J. K., Ahmad, F., Jabbar-Lopez, Z., & Piketty, C. (2022). Pharmacokinetics, Safety, Efficacy, and Biomarker Profiles During Nemolizumab Treatment of Atopic Dermatitis in Adolescents. Dermatology and Therapy. https://doi.org/10.1007/s13555-021-00678-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.